Outcome measures in multimodal rectal cancer trials

Emmanouil Fokas*, Robert Glynne-Jones, Ane Appelt, Regina Beets-Tan, Geerard Beets, Karin Haustermans, Corrie Marijnen, Bruce D. Minsky, Ethan Ludmir, Phil Quirke, David Sebag-Montefiore, Julio Garcia-Aguilar, Maria Antonietta Gambacorta, Vincenzo Valentini, Marc Buyse, Claus Rodel

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)E252-E264
Number of pages13
JournalLancet oncology
Volume21
Issue number5
DOIs
Publication statusPublished - May 2020

Keywords

  • TOTAL MESORECTAL EXCISION
  • SURROGATE END-POINTS
  • RANDOMIZED PHASE-III
  • SHORT-COURSE RADIOTHERAPY
  • DISEASE-FREE SURVIVAL
  • QUALITY-OF-LIFE
  • PREOPERATIVE RADIOTHERAPY
  • FOLLOW-UP
  • POSTOPERATIVE CHEMORADIOTHERAPY
  • LOCAL RECURRENCE

Cite this

Fokas, E., Glynne-Jones, R., Appelt, A., Beets-Tan, R., Beets, G., Haustermans, K., Marijnen, C., Minsky, B. D., Ludmir, E., Quirke, P., Sebag-Montefiore, D., Garcia-Aguilar, J., Gambacorta, M. A., Valentini, V., Buyse, M., & Rodel, C. (2020). Outcome measures in multimodal rectal cancer trials. Lancet oncology, 21(5), E252-E264. https://doi.org/10.1016/S1470-2045(20)30024-3